Linagliptin vs Saxagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Reported efficacy
The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)
Result source: NCT01243424
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Linagliptin | Saxagliptin |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT00954447129 other results
| -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
|
| Body weight, change (kg) | 1.4 vs -0.0+1.5 vs placeboNCT034295434 other results
| -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
|
| HbA1c below 7% | 26.9% vs 24.5%+2.4 vs placeboNCT034295437 other results
| 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
|
| Fasting plasma glucose, change | -0.1 vs 0.0−0.2 vs placeboNCT0095444795 other results
| -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
|
| 3-point MACE (% with event) | 20.7% vs 21.2%vs GlimepirideNCT012434242 other results
| 7.4% vs 7.4%±0 vs placeboNCT01107886 |
HbA1c, change
- Linagliptin
- -0.6% vs 0.1%−0.6 vs placeboNCT00954447
129 other results
- -0.7% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.6% vs -0.0% NCT01792518
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.5% vs -0.1% NCT01087502
- -1.1% vs -0.6% NCT00641043
- -0.4% vs 0.3% NCT00621140
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.7% vs 0.1% NCT01734785
- -0.6% vs -0.2% NCT02897349
- -0.4% vs -0.7% NCT01183013
- 0.3% vs -0.2% NCT03429543
- -1.3% vs -1.6% NCT01708902
- -1.3% vs -1.7% NCT01708902
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -2.1% vs -1.6% NCT01708902
- -2.3% vs -1.6% NCT01708902
- -2.2% vs -1.7% NCT01708902
- -2.4% vs -1.7% NCT01708902
- -0.5% vs 0.1% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.5% vs 0% NCT00954447
- -0.8% vs -0.1% NCT00602472
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.2% NCT01215097
- -0.7% vs -0.2% NCT01214239
- -0.6% vs -0.1% NCT01215097
- -0.9% vs -0.4% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.6% vs -0.1% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.7% vs -0.2% NCT01194830
- -0.6% vs -0.0% NCT01084005
- -0.5% vs -0.1% NCT01214239
- -0.5% vs -0.0% NCT01215097
- -0.6% vs -0.2% NCT00996658
- -0.5% vs 0.1% NCT00601250
- -0.4% vs -0.1% NCT01084005
- -1.1% vs -0.6% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.8% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.8% vs -0.3% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.7% vs -0.2% NCT00602472
- -0.4% vs 0.1% NCT00601250
- -0.4% vs -0.0% NCT00641043
- -0.4% vs 0.1% NCT00621140
- -0.6% vs -0.2% NCT01194830
- -0.5% vs 0.1% NCT03429543
- 0.1% vs 0.1% NCT01243424
- -0.4% vs -0.3% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.5% vs -0.4% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.6% NCT01183013
- -0.5% vs -0.3% NCT01087502
- -0.4% vs -0.4% NCT01183013
- -0.5% vs -0.1% NCT01087502
- -0.5% vs -0.1% NCT01087502
- -0.2% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT01087502
- -0.9% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.2% vs -0.7% NCT01183013
- -0.8% vs -0.6% NCT01183013
- -1.1% vs -0.6% NCT01183013
- -1.2% vs -0.6% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -1.4% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.6% vs -1.2% NCT00915772
- -1.4% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -1.3% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.0% vs -0.4% NCT02240680
- -0.5% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -1.0% vs -1.0% NCT01438814
- -0.6% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- 7.6% vs 8% NCT02004366
- 6.6% vs 8% NCT02004366
- 7% vs 8% NCT02004366
- 8.6% vs 8% NCT02004366
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- 0.1% vs 0.5% NCT03199053
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.4% vs -1.1% NCT02284893
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
Body weight, change (kg)
- Linagliptin
- 1.4 vs -0.0+1.5 vs placeboNCT03429543
4 other results
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 2.7 vs -0.0 NCT03429543
- -0.4 vs -1.1 NCT01438814
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
HbA1c below 7%
- Linagliptin
- 26.9% vs 24.5%+2.4 vs placeboNCT03429543
7 other results
- 13.9% vs 8.2% NCT02897349
- 16.7% vs 24.5% NCT03429543
- 43.6% vs 50% NCT01708902
- 72.1% vs 50% NCT01708902
- 77.1% vs 50% NCT01708902
- 33% vs 10% NCT01012037
- 34% vs 10% NCT01012037
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 44.3% vs 34.3% NCT02419612
- 21.4% vs 11.7% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
Fasting plasma glucose, change
- Linagliptin
- -0.1 vs 0.0−0.2 vs placeboNCT00954447
95 other results
- -0.4 vs -0.2 NCT00954447
- -0.3 vs -0.1 NCT00954447
- -0.4 vs 0.3 NCT00954447
- -0.3 vs 0.2 NCT00954447
- -0.3 vs 0.5 NCT00602472
- -0.5 vs 0.1 NCT01214239
- -0.6 vs -0.1 NCT01215097
- -0.4 vs 0 NCT00954447
- -0.2 vs 0.1 NCT00954447
- -0.6 vs 0.0 NCT00996658
- -0.6 vs 0.6 NCT00601250
- -0.3 vs 0.4 NCT00602472
- -0.6 vs 0.6 NCT00601250
- -0.5 vs 0.3 NCT00602472
- -0.7 vs 0.2 NCT00601250
- -0.6 vs 0.3 NCT00602472
- -0.7 vs 0.3 NCT00601250
- -1.3 vs -0.6 NCT01194830
- -0.6 vs 0.6 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.7 vs -0.1 NCT01215097
- -0.5 vs -0.1 NCT00996658
- -0.7 vs 0.5 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.8 vs -0.3 NCT01215097
- -0.4 vs -0.0 NCT00954447
- -0.4 vs 0.2 NCT00996658
- -0.8 vs 0.4 NCT01084005
- -0.7 vs -0.0 NCT01214239
- -0.9 vs 0.3 NCT01215097
- -0.2 vs 0.7 NCT00996658
- -0.8 vs 0.3 NCT01084005
- -1.8 vs 0.3 NCT01734785
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.0 NCT00641043
- -0.5 vs 0.8 NCT00621140
- -1.8 vs -1.1 NCT00641043
- -0.4 vs 0.7 NCT00621140
- -1.9 vs -1.1 NCT00641043
- -0.6 vs 0.6 NCT00621140
- -1.9 vs -0.9 NCT00641043
- -0.6 vs 0.4 NCT00621140
- 0.2 vs -0.2 NCT01087502
- -0.1 vs -0.1 NCT01087502
- -0.1 vs -0.0 NCT01087502
- -0.1 vs -0.6 NCT01087502
- -0.1 vs -1.6 NCT01183013
- 0 vs -1.4 NCT01183013
- -0.5 vs -0.5 NCT01087502
- -0.8 vs -1.7 NCT01708902
- -0.3 vs -1.2 NCT01183013
- -0.7 vs -0.5 NCT01087502
- -0.3 vs -0.5 NCT01087502
- -0.4 vs -1.1 NCT01183013
- -0.4 vs -1.2 NCT01183013
- 0.0 vs 0.5 NCT01087502
- -0.3 vs 0.3 NCT01087502
- -0.6 vs 0.5 NCT01087502
- -0.2 vs -0.9 NCT01183013
- -0.6 vs 0.5 NCT01087502
- -1.1 vs -1.6 NCT01183013
- -1.5 vs -1.6 NCT01183013
- -1.9 vs -1.6 NCT01183013
- -1 vs -1.4 NCT01183013
- -1.5 vs -1.4 NCT01183013
- -1.9 vs -1.4 NCT01183013
- -0.9 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.1 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1 vs -1.2 NCT01183013
- -1.7 vs -1.2 NCT01183013
- -1.6 vs -1.2 NCT01183013
- -1.1 vs -0.9 NCT01183013
- -1.5 vs -0.9 NCT01183013
- -1.6 vs -0.9 NCT01183013
- -0.4 vs -0.3 NCT00915772
- -0.6 vs -0.3 NCT00915772
- -0.5 vs -0.4 NCT00915772
- -0.7 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -2.2 vs -1.7 NCT01708902
- -2.6 vs -1.7 NCT01708902
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.8 vs -0.2 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.6 vs -0.2 NCT00915772
- -1.2 vs -0.2 NCT01012037
- -0.9 vs -0.2 NCT01012037
- -1.4 vs -1.5 NCT01438814
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
3-point MACE (% with event)
- Linagliptin
- 20.7% vs 21.2%vs GlimepirideNCT01243424
2 other results
- 11.8% vs 12% NCT01243424
- 12.4% vs 12.1% NCT01897532
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Linagliptin: 13 of 13 rows · Saxagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Linagliptin Rows use multiple source trials | Saxagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -1.68 mmol/L @ 24wk*5 mga,b NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted show 3 more doses-1.67 mmol/L @ 24wk*5 mg NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted -2.61 mmol/L @ 24wk*5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted | -0.55 mmol/L @ 24wkb NCT01608724 · Phase 4 · registry result, not featured evidence 1 other source trial-0.62 mmol/L @ 24wk* NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -11.3 vs 0.2 placebo mg @ 24wk5 mgc,b,d NCT02240680 · Phase 4 · registry result, not featured evidence 1 other source trial-5.5 vs 0.7 placebo mg @ 24wk NCT02897349 · Phase 3 · registry result, not featured evidence | -27.53 vs -19.95 Dapagliflozin + Metformin mg @ 24wkc,b,d NCT02681094 · Phase 3 · registry result, not featured evidence · add on |
| Glycemic Rescue responder rate · % of participants | 7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,b,e NCT01708902 · Phase 3 · registry result, not featured evidence show 2 more doses2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination | 37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mgb,e NCT02419612 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=113) @ 24wk5 mga,c,b NCT01512979 · Phase 4 · registry result, not featured evidence show 3 more doses-2.01% (n=113) @ 24wk5 mg NCT01512979 · Phase 4 · registry result, not featured evidence -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination -2.81% (n=132) @ 24wk5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination | -0.64% (n=229) @ 24wkc,b NCT02104804 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c 7.0 or Less event count · % of participants | 21.7% (n=618) vs 9.1% (n=617) placebo @ 24wk*5 mgb,d NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 134 Participants as posted | 30.7% (n=127) vs 9.4% (n=127) placebo @ 24wk*b,d NCT01128153 · Phase 3 · registry result, not featured evidence · converted to % from 39 Participants as posted |
| HbA1c Less Than 7 absolute value · percentage points | 22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mgf,b,d NCT01087502 · Phase 3 · registry result, not featured evidence | 44.7% (n=356) vs 54.7% (n=353) Glimepiride @ 52wk5 mgf,b,d NCT01006603 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7% event count · % of participants | 48% (n=196) vs 27.7% (n=94) placebo @ 24wk*5 mga,b,d NCT01214239 · Phase 3 · registry result, not featured evidence · converted to % from 94 Patients as posted show 1 more dose45.5% (n=176) vs 25.8% (n=89) placebo @ 24wk*5 mg NCT01214239 · Phase 3 · registry result, not featured evidence · converted to % from 80 Patients as posted | 42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*b,d NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 27.1% (n=70) @ 12wk5 mg QDa,f,b NCT01708902 · Phase 3 · registry result, not featured evidence show 1 more dose58.8% (n=68) @ 12wk2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination | 45.6% (n=1210) @ 12wkf,b NCT01608724 · Phase 4 · registry result, not featured evidence |
| PPG 2h Change mg/dL absolute change · mmol/L | -2.71 vs 1.01 placebo mmol/L @ 24wk*b,g NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted 3 other source trials-1.78 vs 0 placebo mmol/L @ 24wk* NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted -2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted -1.86 vs 1.38 placebo mmol/L @ 24wk* NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted | -4.08 vs -2.11 placebo mmol/L @ 24wk*b,g NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted 2 other source trials-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted -1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted |
| Dropout rate | 7.3%h NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results7.5% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.3% NCT01243424 · Phase 3 0% NCT02467478 · Phase 4 · registry result, not featured evidence 15%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 24% NCT01897532 · Phase 4 · registry result, not featured evidence 5.3%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 20% NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.8%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 9.9%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 11.6%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 9.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 10.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 22.2%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 6.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 9%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 6.8%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 11.3%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 2.4%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 3.7%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 12.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 6.8%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.7%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 24.5%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.9%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 17%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 20.4%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 21.2% NCT00740051 · Phase 3 · registry result, not featured evidence 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 5.4% NCT00621140 · Phase 3 · registry result, not featured evidence 4.5%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 7.2%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 22.7%10 mgi NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 2.9%h NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results1.7% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 — NCT01243424 · Phase 3 — NCT02467478 · Phase 4 · registry result, not featured evidence —5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 10.3% NCT01897532 · Phase 4 · registry result, not featured evidence 4%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination — NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 2.2%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 4.2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 4.8%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 3.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.4%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 2%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 1.5%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.7%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 1.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.4%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 4%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.8%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 4.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 2.6% NCT00740051 · Phase 3 · registry result, not featured evidence 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00621140 · Phase 3 · registry result, not featured evidence 1.3%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 3.6%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 2.8%10 mgi NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 3.2%h NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results3.4% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.4%5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 46.4% NCT01243424 · Phase 3 7.1% NCT02467478 · Phase 4 · registry result, not featured evidence 0%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 37% NCT01897532 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 12.6%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 25%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0.8%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence 13%Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence 15.1%Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 23.1%Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 15% NCT02350478 · Phase 4 · registry result, not featured evidence 5.3% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 9.6% NCT02897349 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 9.3%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 3.2%5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.5%2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 0.7%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 24.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 0.5%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 2%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.2%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 8.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.8%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.6%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.7%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0.9%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.8%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.3%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 8.6%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 0.7% NCT00740051 · Phase 3 · registry result, not featured evidence 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 3% NCT00621140 · Phase 3 · registry result, not featured evidence 2.2%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 4%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 12.2%10 mgi NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | h hypoglycaemia 22.7% (placebo 14.8%) upper respiratory tract infection 5.8% (placebo 9.1%) hyperglycaemia 5.6% (placebo 8.7%) NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 50 more resultshyperglycaemia 5.2% (placebo 14.7%) nasopharyngitis 5.2% (placebo 5.1%) NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 20.8% (placebo 12.1%) headache 15.6% (placebo 15.5%) blood ketone body increased 10.4% (placebo 3.4%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 hypoglycaemia 29.3% (placebo 28.8%) hypertension 6.2% (placebo 6.7%) hyperglycaemia 6% (placebo 6.9%) NCT01897532 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 33.8% (placebo 25.2%) viral upper respiratory tract infection 7.3% (placebo 5.3%) urinary tract infection 6.6% (placebo 6%) NCT02240680 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 38.5% (placebo 25.2%) viral upper respiratory tract infection 21.2% (placebo 5.3%) bronchitis 9.6% (placebo 2.6%) NCT02240680 · Phase 4 · registry result, not featured evidence infections 5.5% renal 4.7% surgical reintervention 4.7% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% musculoskeletal 1.1% skin 1.1% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination gastrointestinal 0% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination dorsal pain 5% (placebo 0%) nausea 5% (placebo 4.3%) toothache 5% (placebo 0%) NCT02350478 · Phase 4 · registry result, not featured evidence increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%) pneumonia 5.3% (placebo 0%) cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%) NCT01969084 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 17.3% (placebo 12.7%) upper respiratory tract infection 13.5% (placebo 12.7%) hyperuricaemia 5.8% (placebo 1%) NCT02897349 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 13.2% (placebo 5.6%) nasopharyngitis 7.1% (placebo 5.6%) upper respiratory tract infection 2.2% (placebo 5.1%) NCT01792518 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 5 mg diarrhoea 3% hyperuricaemia 3% dizziness 0% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperglycaemia 16.9% hyperuricaemia 5.6% nasopharyngitis 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperuricaemia 7.5% hyperglycaemia 4.8% upper respiratory tract infection 4.1% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD, then 2.5 mg / Metformin after week 12 hyperuricaemia 19.4% dizziness 6.5% hyperglycaemia 6.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg hyperuricaemia 6.2% hyperglycaemia 3.1% diarrhoea 1.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 5.6% hyperuricaemia 5.6% upper respiratory tract infection 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 9.5% hyperuricaemia 7.5% upper respiratory tract infection 7.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 500 mg BID upper respiratory tract infection 8.2% hyperuricaemia 5.4% diarrhoea 4.8% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperglycaemia 10.4% nasopharyngitis 7.4% hypertension 6.7% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 59.3% nasopharyngitis 18.6% hyperglycaemia 17.7% NCT01087502 · Phase 3 · registry result, not featured evidence 5 mg hyperlipidaemia 5.5% (placebo 3%) hyperglycaemia 2% (placebo 4%) NCT01214239 · Phase 3 · registry result, not featured evidence 5 mg once daily hyperglycaemia 4.9% (placebo 5%) hyperlipidaemia 4.4% (placebo 4%) diarrhoea 2.4% (placebo 1%) NCT01215097 · Phase 3 · registry result, not featured evidence 5 mg tablet anaemia 7.1% (placebo 6.7%) hyperglycaemia 6% (placebo 7.9%) hypoglycaemia 5.5% (placebo 4.5%) NCT00996658 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.2% back pain 5.9% constipation 5.9% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 36.6% bronchitis 11% arthralgia 6.1% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 45.5% pharyngitis 7.6% constipation 4.5% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 33.8% upper respiratory tract inflammation 8.1% arthralgia 5.4% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 31.5% hypoglycaemia 14% contusion 7% NCT01204294 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 6.6% (placebo 3.3%) hyperglycaemia 2.8% (placebo 9.2%) NCT01194830 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 30.3% (placebo 31.3%) hyperglycaemia 14.3% (placebo 17.8%) nasopharyngitis 11.3% (placebo 9.8%) NCT00954447 · Phase 3 · registry result, not featured evidence linagliptin 2.5 mg bid + metformin 1000 mg bid diabetes mellitus 9.9% diarrhoea 7% nasopharyngitis 7% NCT00915772 · Phase 3 · registry result, not featured evidence · combination linagliptin 2.5 mg bid + metformin 500 mg bid hyperglycaemia 12.9% diabetes mellitus 8% glomerular filtration rate decreased 6.2% NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 22.8% (placebo 16.5%) nasopharyngitis 10.5% (placebo 8.9%) diarrhoea 5.6% (placebo 2.5%) NCT01084005 · Phase 3 · registry result, not featured evidence hyperglycaemia 14.6% nasopharyngitis 9.9% dizziness 7.3% NCT00740051 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination hyperglycaemia 8.6% (placebo 22.8%) NCT00621140 · Phase 3 · registry result, not featured evidence | 10 mgi influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTrial phases differ: Phase 4 versus Phase 3.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 24 weeks versus 156 weeks.
- fTrial phases differ: Phase 3 versus Phase 4.
- gTreatment context differs: monotherapy versus combination.
- hPopulation comparability has not been reviewed for 55 of these studies.
- iPopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Linagliptin
show 9 more results
show 1 more result
show 1 more result
show 1 more result
show 7 more results
+ 46 further endpoints in the CSV export.
Saxagliptin
show 8 more results
show 6 more results
show 3 more results
show 4 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
+ 36 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Saxagliptin's landscape